Abstract
Ibandronate is a third-generation aminobisphosphonate that has an excellent safety record in hypercalcaemia of malignancy, and has recently been approved for the prevention of skeletal events from metastatic breast cancer. This paper reviews the safety data from clinical studies of intravenous ibandronate by infusion or injection, focusing on renal adverse events (AEs). In clinical trials of patients with hypercalcaemia of malignancy, 2-h infusions of ibandronate at doses of up to 6 mg had a low potential for renal events. In a phase III trial of patients with metastatic bone disease from breast cancer, 6 mg ibandronate infused over 1-2 h had a renal safety profile comparable to that of placebo. In pilot studies, repeated daily infusions of ibandronate (4 mg infused over 2 h for four consecutive days, or 6 mg infused over 1 h for three consecutive days) for severe metastatic bone pain were not associated with any renal AEs. The safety of single 15-min infusions of 6 mg ibandronate has been demonstrated in healthy volunteers and patients with metastatic bone disease from breast cancer or multiple myeloma. Furthermore, single and rapid bolus injections of 2 or 3 mg ibandronate did not increase the risk of renal dysfunction in pat...Continue Reading
References
Feb 26, 1983·Lancet·H M BounameauxF Chatelanat
Aug 1, 1993·Bone and Mineral·C WüsterS H Scharla
Jan 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M PecherstorferD Thiébaud
Mar 1, 1996·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·S Adami, N Zamberlan
Jan 1, 1997·British Journal of Cancer·S H RalstonJ J Body
May 1, 1996·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·M PecherstorferJ J Body
Dec 20, 1999·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·N ZojerM Pecherstorfer
Jun 1, 2000·Breast Cancer Research and Treatment·E F SolomayerG Bastert
Sep 7, 2001·Seminars in Oncology·R E Coleman
Mar 1, 2002·The Cochrane Database of Systematic Reviews·N Pavlakis, M Stockler
Mar 20, 2002·Clinical Breast Cancer·I J DielG Bastert
Jun 5, 2003·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Debasish BanerjeeDavid Roth
Jun 5, 2003·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·M PecherstorferB Bergström
Jun 6, 2003·Kidney International·Glen S MarkowitzVivette D D'Agati
Sep 5, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J-J BodyUNKNOWN MF 4265 Study Group
Sep 11, 2003·Toxicology·Thomas PfisterFrieder Bauss
Sep 26, 2003·The New England Journal of Medicine·Bernard S Chang, Daniel H Lowenstein
Oct 10, 2003·Cancer·Lee S RosenJohn J Seaman
Oct 24, 2003·The New England Journal of Medicine·Jennie T ChangJulie Beitz
Jun 1, 2007·Clinical Drug Investigation·Nina V LyubimovaKarl Schlosser
Citations
Nov 24, 2006·Clinical Rheumatology·Johann D Ringe, Parvis Farahmand
Jun 1, 2005·Clinical Therapeutics·Paul D Miller
May 26, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E TerposUNKNOWN European Myeloma Network
Nov 30, 2007·Clinical Interventions in Aging·Philip Sambrook
Mar 25, 2006·Future Oncology·Ingo J Diel
May 5, 2005·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·E De CockG Lewis
Dec 7, 2006·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Raja S BobbaJonathan D Adachi
Jul 6, 2011·The Breast : Official Journal of the European Society of Mastology·Xavier PivotL Frimat
Apr 28, 2006·Pharmacotherapy·David R P Guay
Mar 17, 2010·Journal of Chemotherapy·I MeattiniG Biti
Oct 4, 2006·Acta Haematologica·Dirk HenrichRaoul Bergner
Nov 30, 2007·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Karin Olson, Catherine Van Poznak
Oct 2, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M AaproB Thürlimann